The FDA Has Approved ADMA Biologics' Ninth ADMA Biocentres Plasma Collection Facility Located In Dallas, GA; The Plasma Collection Facility Commenced Operations And Initiated Source Plasma Collection In Q3 2022
Portfolio Pulse from Benzinga Newsdesk
The FDA has approved ADMA Biologics' ninth plasma collection facility located in Dallas, GA. The facility began operations and initiated source plasma collection in Q3 2022.

July 19, 2023 | 11:05 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ADMA Biologics' ninth plasma collection facility has received FDA approval and began operations in Q3 2022.
The FDA approval of ADMA Biologics' ninth plasma collection facility is a positive development for the company. It expands their capacity to collect plasma, which is crucial for their operations. This could potentially lead to increased revenues in the future, which is likely to have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100